查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1546126

登革热疫苗市场规模：疫苗类型、疫苗阶段、通路、区域前景、竞争策略、细分市场预测（截至2033年）

Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel- Regional outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 247 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计2033年全球登革热疫苗市场规模将成长至18.1395亿美元，预测期内复合年增长率为13.11%。

本报告调查了全球登革热疫苗市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场/地区/主要国家的详细分析、竞争格局和主要企业概况的集合。

目录

第一章简介

第二章调查方法

第三章执行摘要

第四章市场动态

  • 促进因素、抑制因素、机会与挑战分析
  • COVID-19 对市场的影响

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争状况

  • 製造地、销售区域、产品类型分布
  • 併购、联盟、产品发布、合作

第七章全球登革热疫苗市场：依疫苗类型

  • 全球市场规模、份额和预测
  • 减毒活疫苗
  • 重组疫苗

第八章全球登革热疫苗市场：依疫苗阶段划分

  • 全球市场规模、份额和预测
  • 第一阶段
  • 第二阶段
  • 第三阶段

第九章全球登革热疫苗市场：依通路划分

  • 全球市场规模、份额和预测
  • 合成
  • 生物基

第十章全球登革热疫苗市场预测

  • 市场规模/市场占有率

第十一章全球登革热疫苗市场：按地区

  • 市场规模/市场占有率趋势/预测
  • 亚太地区
  • 欧洲
  • 中东/非洲
  • 北美洲
  • 拉丁美洲

第十二章 公司简介

  • Butantan Institute
  • GeneOne Life Science Inc.
  • GlaxoSmithKline Plc
  • Mylan NV
  • Medigen Vaccine Biologics Corporation
  • Merck and Co. Inc.
  • Nunn's Home Medical Equipment Company Ltd.
  • Panacea Biotec Limited
  • Sanofi Pasteur Limited
  • Serum Institute of India Pvt. Ltd.

第13章结论

第14章简称

第十五章 参考链接

简介目录
Product Code: PHAR2411

Dengue Vaccines Market Introduction and Overview

According to SPER Market Research, 'Dengue Vaccines Market Size- By Type of Vaccine, By Vaccine Phase, By Distribution Channel - Regional outlook, Competitive Strategies and Segment Forecast to 2033' States that the Global Dengue Vaccines Market is estimated to reach USD 1813.95 million by 2033 with a CAGR of 13.11 %.

Dengue vaccines are designed to prevent dengue fever, a tropical illness spread by Aedes mosquitoes. The primary challenge in developing these vaccines lies in addressing the four different dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4).

The focus on COVID-19 diverted resources, funding, and research efforts away from other infectious diseases, including dengue. This shift has slowed progress in the development and approval of new dengue vaccines.

Scope of the report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Type of Vaccine, By Vaccine Phase, By Distribution Channel

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Butantan Institute, GeneOne Life Science Inc., GlaxoSmithKline Plc, Mylan N.V., Medigen Vaccine Biologics Corporation, Merck and Co. Inc., Nunn's Home Medical Equipment Company Ltd., Panacea Biotec Limited, Sanofi Pasteur Limited, Serum Institute of India Pvt Ltd.

Global Dengue Vaccines Market Segmentation:

By Type of Vaccine: Based on the Type of Vaccine, Global Dengue Vaccines Market is segmented as; Live Attenuated Vaccines, Recombinant Vaccines.

By Vaccine Phase: Based on the Vaccine Phase, Global Dengue Vaccines Market is segmented as; Phase I, Phase II, Phase III.

By Distribution Channel: Based on the Distribution Channel, Global Dengue Vaccines Market is segmented as; Hospitals, Clinics, Retail Pharmacies.

By Region: This research also includes data for North America, Asia-Pacific, Latin America, Middle East & Africa and Europe.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Dengue Vaccines Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Dengue Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type of Vaccine
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dengue Vaccines Market

7. Global Dengue Vaccines Market, By Type of Vaccine (USD Million) 2020-2033

  • 7.1. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2020-2026
  • 7.2. Global Dengue Vaccines Market Size, Share and Forecast, By Type of Vaccine, 2027-2033
  • 7.3. Live Attenuated Vaccines
  • 7.4. Recombinant Vaccines

8. Global Dengue Vaccines Market, By Vaccine Phase (USD Million) 2020-2033

  • 8.1. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2020-2026
  • 8.2. Global Dengue Vaccines Market Size, Share and Forecast, By Vaccine Phase, 2027-2033
  • 8.3. Phase I
  • 8.4. Phase II
  • 8.5. Phase III

9. Global Dengue Vaccines Market, By Distribution Channel (USD Million) 2020-2033

  • 9.1. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2020-2026
  • 9.2. Global Dengue Vaccines Market Size, Share and Forecast, By Distribution Channel, 2027-2033
  • 9.3. Synthetic
  • 9.4. Bio-Based

10. Global Dengue Vaccines Market Forecast, 2020-2033 (USD Million)

  • 10.1. Global Dengue Vaccines Market Size and Market Share

11. Global Dengue Vaccines Market, By Region, 2020-2033 (USD Million)

  • 11.1. Global Dengue Vaccines Market Size and Market Share By Region (2020-2026)
  • 11.2. Global Dengue Vaccines Market Size and Market Share By Region (2027-2033)
  • 11.3. Asia-Pacific
    • 11.3.1. Australia
    • 11.3.2. China
    • 11.3.3. India
    • 11.3.4. Japan
    • 11.3.5. South Korea
    • 11.3.6. Rest of Asia-Pacific
  • 11.4. Europe
    • 11.4.1. France
    • 11.4.2. Germany
    • 11.4.3. Italy
    • 11.4.4. Spain
    • 11.4.5. United Kingdom
    • 11.4.6. Rest of Europe
  • 11.5. Middle East and Africa
    • 11.5.1. Kingdom of Saudi Arabia
    • 11.5.2. United Arab Emirates
    • 11.5.3. Qatar
    • 11.5.4. South Africa
    • 11.5.5. Egypt
    • 12.5.6. Morocco
    • 11.5.7. Nigeria
    • 11.5.8. Rest of Middle-East and Africa
  • 11.6. North America
    • 11.6.1. Canada
    • 11.6.2. Mexico
    • 11.6.3. United States
  • 11.7. Latin America
    • 11.7.1. Argentina
    • 11.7.2. Brazil
    • 11.7.3. Rest of Latin America

12. Company Profile

  • 12.1. Butantan Institute
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. GeneOne Life Science Inc.
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. GlaxoSmithKline Plc
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Mylan N.V.
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. Medigen Vaccine Biologics Corporation
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. Merck and Co. Inc.
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. Nunn's Home Medical Equipment Company Ltd.
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. Panacea Biotec Limited
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Sanofi Pasteur Limited
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Serum Institute of India Pvt. Ltd.
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments

13. Conclusion

14. List of Abbreviations

15. Reference Links